Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary drug delivery systems in the treatment of various disorders including human pancreatic cancer and colon cancer. The work the Company is contracting to conduct is intended to do pre-clinical trials leading into seeking FDA approval for the combined efforts. Our team of industry experts and advisors have the expertise to lead the Company to efficiently conduct this next phase of development.
The developing program will allow Oncology Pharma to begin its own path towards producing proprietary intellectual property, for the pursuit and development of new therapies. The Company's established portfolio of licensing agreements is expected to allow the company the ability to develop its own innovations to stand out amongst its peers.
https://finance.yahoo.com/news/oncology-pharma-inc-entering-next-120000837.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.